American cancer vaccine patent boost $PCIB.OL over falling wedgePCI Biotech: US patent granted for the vaccine technology (fimaVACC) in combination with cytokines
Oslo (Norway), 21 January 2020 – PCI Biotech OSL:PCIB , a cancer focused biopharmaceutical company, today announces that the U.S. Patent and Trademark Office (USPTO) has granted the company a US patent covering the use of fimaVacc in combination with cytokines.
Cytokines are small proteins that are involved in cell signaling, and that are very important in the immune system, modulating both cel
P
BerGenBio SMA50/200 golden cross tests breakout upon new dataABOUT BERGENBIO
OSL:BGBIO
BerGenBio is a clinical-stage oncology company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers.
www.bergenbio.com
www.nordnet.no
Trinity Delta Analysis:
www.trinitydelta.org
B
EQUINOR (EQNR) | Important Signs For Further Growth!Hi,
Equinor ASA , an energy company, explores for, produces, transports, refines and markets petroleum and petroleum-derived products, and other forms of energy in Norway and internationally.
Fundamental pros:
1. Trading below its fair value.
2. Good PE and PEG ratio.
3. Earnings are forecasted to grow.
4. A lot of insider buying.
Technical pros:
The correction, which started at the end of 2018, has started to show some positive signs for further growth.
1. The price has made a breakout
LERØY SEAFOOD (LSG) | Strong Fundamentally & Technically!Hi,
Lerøy Seafood Group produces, processes, markets, and distributes fresh, frozen, and smoked seafood products in Norway.
It shows pretty good value numbers, it is way undervalued, insiders (CEO) have bought the stock recently (actually yesterday) and etc.
Fundamentally, Lerøy Seafood looks quite good and most importantly, technically as well. There is a perfect area where you can invest or reinvest to Lerøy Seafood, the area consists of:
1) Weekly EMA200
2) Monthly EMA50
3) The round numb
PCI Biotech $PCIB.OL top 10 hot nordic stocks @veckansaffarer
www.va.se
finansavisen.no
PCI Biotech OSL:PCIB is a biopharmaceutical company focusing on development and commercialisation of novel therapeutic solutions for improved treatment of cancer patients through its innovative photochemical internalisation (PCI) technology platform. PCI induces triggered endosomal release that can be used to unlock the true potential of a wide array of therapeutic modalities.
The company is applying PCI to three distinct anticancer paradigms:
• fimaCH
P
Snapshot / observation, climbBrokers Clarksons Platou covers Bonheur (17 Des), and sets objective at NOK 285.
I have suggested both average support and resistance levels in red and blue, and the green upwards trend is self explaining. Holding medium sized position waiting for the (presumptive) January effect.
If the objective is sound and realistic, there should still be plenty time to get aboard.
Bakkafrost, at the top of everything?Bakkafrost looks to be closing to the top of everything, IF previous pattern repeats itself. From just half a year ago Bakkafrost could be bought at around 440 NOK followed by a steady rise to a current 640 NOK. This is a staggering 50% increase in just half a year.
That alone is not the only factor Bakkafrost has against a further rise. We also see that if the Impulse Elliot Waves repeats itself we are close to an A,B,C elliot correction. Or even an A,B,C,D correction. But time will show.
A
BerGenBio $BGBIO.OL rallies amid Norwegian biotech optimismBerGenBio OSL:BGBIO is a norwegian clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers.
The stock is currently in a short term uptrend that could provide a new test of important resistance, where a breakout to the upside could trigger a powerful buy signal.
Sponsored analyst summary:
www.trinitydelta.org
Twitter:
twitter.com
BLong
Telenor nearing buy zone Telenor is currently in a bearish trend, but it's nearing the area where one should look to buy.
We have two significant horisontal supports. The first @ 156.75, and the second at 150.45.
The logic game plan for me, is to place equal bids at the two levels. Making the potential average cost 153.6.
TP 1: 180
(TP 2: 190)
Yara bet x 338As we can see from the 1hr here, price bounced off support at 338 at decent volume. This indicates a switch in momentum to the north.
I see resistance at 370 as the target price. But be aware that 200MA will probably provide some resistance first, since it has been well respected in this downtrend.
NB: Entry, SL & TP is calculated from 338, price is now trading at 446.xx
Twin peaks or blue book dream?Any thoughts on this scenario? would P1 and P2 qualify as double peak (supposedly a bullish formation), and is it in your opinion consistent with the later emerging upward trend (double channel)?
As I understand it, a prerequisite for a bullish development is the high traded volume at Peak2 (bottom).
Any opinions and contributions much appreciated!
Possible horizontal development Another attempt to identify the development for the stock in which I hold my largest position. This multi disciplinary "national treasure" company, with very long lines back to the original Fred. Olsen-company, is ideal for me to practice on. It´s stable development trends is very forgiving for the rookie eye to experiment with.
Now, a possible horizontal movement could be under development after a long and steady climb. I will make an attempt at possible future developments based on this presch























